Properties (49)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemical compound
|
| gptkbp:campusFacilities |
gptkb:ABC_University
|
| gptkbp:chemicalFormula |
stable under normal conditions
lipophilic small molecule hydrophilic C20H24N2O2 contains thiazole ring MSDS available contains_benzothiazole_moiety |
| gptkbp:clinicalTrials |
gptkb:USA
Phase II promising |
| gptkbp:compatibleWith |
high
|
| gptkbp:composedOf |
multi-step synthesis
|
| gptkbp:contraindication |
anxiety
insomnia weight gain |
| gptkbp:dissolved |
soluble in DMSO
|
| gptkbp:dosageForm |
tablet
|
| gptkbp:drugInterdiction |
gptkb:MAO_inhibitors
SSRIs |
| gptkbp:enrollment |
adults
|
| gptkbp:funding |
government grant
|
| https://www.w3.org/2000/01/rdf-schema#label |
WPC-566
|
| gptkbp:impact |
dizziness
nausea dry mouth |
| gptkbp:isATypeOf |
123456-78-9
|
| gptkbp:market |
not yet marketed
|
| gptkbp:operational_status |
clinical trials
|
| gptkbp:origin |
(2S)-2-(4-(4-(dimethylamino)phenyl)-1,3-thiazol-2-yl)-1-(4-fluorophenyl)ethyl)-1,3-benzothiazole-6-carboxylic acid
|
| gptkbp:patentStatus |
patented
|
| gptkbp:publications |
gptkb:Pharmacology_Biochemistry_and_Behavior
Neuropharmacology Journal of Medicinal Chemistry Clinical Psychopharmacology Psychiatric_Research |
| gptkbp:related_to |
WPC-567
|
| gptkbp:releaseYear |
2010
|
| gptkbp:research_areas |
psychiatry
|
| gptkbp:route |
oral
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:sponsor |
gptkb:XYZ_Pharmaceuticals
|
| gptkbp:storage |
room temperature
|
| gptkbp:targets |
serotonin receptor
|
| gptkbp:triggerType |
serotonin reuptake inhibitor
|
| gptkbp:uses |
antidepressant
|
| gptkbp:weight |
324.42 g/mol
|